SEC Form 13F
| Report period | 2026-06-30 |
|---|---|
| Publicly available | 2026-08-08 |
| Reported value | $451,627,235 |
| Positions | 6 |
| Issuer | Ticker | Class | Reported value | Reported amount |
|---|---|---|---|---|
| Oruka Therapeutics Inc | ORKA | COM | $149,003,957 | 1,565,661 |
| Spyre Therapeutics Inc | SYRE | COM | $129,988,924 | 1,464,169 |
| Apogee Therapeutics Inc | APGE | COM | $77,871,496 | 586,691 |
| Damora Therapeutics Inc | DMRA | COM | $53,202,753 | 2,045,473 |
| Jade Biosciences Inc | JBIO | COM | $35,057,605 | 1,577,750 |
| Crescent Biopharma Inc | CBIO | COM | $6,502,500 | 361,250 |
Public filing evidence only. NexusTrade's simulated follower strategies are hypothetical, modeled results — not live trading returns and not investment advice.